GNLX
Genelux Corporation Common Stock
NASDAQ: GNLX · HEALTHCARE · BIOTECHNOLOGY
$2.67
+6.80% today
Updated 2026-04-30
Market cap
$114.70M
P/E ratio
—
P/S ratio
14,337.86x
EPS (TTM)
$-0.86
Dividend yield
—
52W range
$2 – $9
Volume
0.2M
Genelux Corporation Common Stock (GNLX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-117,650.00%
ROE
-170.00%
ROA
-77.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | — | $-11.63M | — | — | — |
| 2020 | $0.00 | $-14.86M | — | — | — |
| 2021 | $0.00 | $-17.80M | — | — | — |
| 2022 | $11.07M | $-5.21M | 91.25% | -27.22% | -47.05% |
| 2023 | $170000.00 | $-28.30M | -498.82% | -14,214.71% | -16,645.29% |
| 2024 | $8000.00 | $-29.87M | -11,187.50% | -396,200.00% | -373,362.50% |
| 2025 | $8000.00 | $-32.15M | -7,075.00% | -415,175.00% | -401,812.50% |